GLI1 and medulloblastoma: The group addressed this issue by nanoformulating HPI-1 (NanoHHI) that is a potent antagonist of Gli1 and reported that NanoHHI markedly inhibits the growth of mouse medulloblastoma allografts, which harbor a SmoD477G-binding site mutation, accompanied by significant downregulation of Gli1 mRNA.